By Marisa Taylor and Dan Levine
(Reuters) -Top U.S. health officials believe that Pfizer Inc’s COVID-19 vaccine could be authorized for children aged 5-11 years old by the end of October, two sources familiar with the situation said on Friday.
The timeline is based on the expectation that Pfizer, which developed the shot with Germany’s BioNTech, will have enough data from clinical trials to seek emergency use authorization (EUA) for that age group from the U.S. Food and Drug Administration (FDA) towards the end of this month, the sources said.
They anticipate the FDA could make a decision on whether the shot is safe and effective in younger children within three weeks of the EUA submission.
Top U.S. infectious disease expert Dr. Anthony Fauci outlined the timetable during an online town hall meeting attended by thousands of staff at the National Institutes of Health (NIH) on Friday, according to one of the sources. A second source familiar with the situation said that the FDA anticipated a similar timeline for Pfizer. If Pfizer submits its EUA by the end of September, and the data support its use, “by the time we get to October, the first couple of weeks of October … the Pfizer product will likely be ready,” Fauci said, according to the source. Fauci said that Moderna Inc will likely take about three weeks longer than Pfizer to collect and analyze its data on children age 5-11, according to the source. He estimated that a decision on the Moderna shot could come around November, according to the source. The second source said Fauci’s timeline for Moderna appeared “optimistic.” NIH officials did not immediately comment on the Fauci remarks. Pfizer has said that it would have data on children age 5-11 ready in September and planned to submit for an EUA shortly after. Previously, federal health regulators, including Fauci have suggested that an FDA decision might come in November or later. Moderna on Thursday told investors it expected data from its children’s study by the end of the year.
(Reporting by Marisa Taylor in Washington and Dan Levine in San Francisco; Editing by Michele Gershberg, Caroline Humer)
